The authors exploited atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia.
[Journal of Nanobiotechnology]
7992332
{7992332:AAAAAAAA}
apa
50
1
167461
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/